For the quarter ending 2025-09-30, CNTB had -$2,787K decrease in cash & cash equivalents over the period. -$17,440K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -17,200 | -23,171 |
| Share-based compensation expense | 916 | 1,893 |
| Depreciation and amortization | 179 | 344 |
| Accretion of discounts on available-for-sale investments | 169 | 537 |
| Loss on disposal of property and equipment | 0 | -34 |
| Accounts receivable, net | 17 | -789 |
| Prepaid expenses and other assets | 1,811 | 3,524 |
| Other non-current assets | -1 | 7 |
| Accounts payable | -300 | 1,952 |
| Accrued liabilities | 999 | 131 |
| Contract liabilities | 1 | 0 |
| Operating lease liabilities | -1 | 56 |
| Contract assets | - | 0 |
| Other non-current liabilities | -4 | -510 |
| Net cash used in operating activities | -17,406 | -22,550 |
| Purchases of short-term investments | 0 | 30,470 |
| Proceeds from maturities and sales of short-term investments | 14,380 | 15,340 |
| Purchases of property and equipment | 34 | 384 |
| Proceeds from sale of property and equipment | 0 | 2 |
| Net cash (used in) provided by investing activities | 14,346 | -15,512 |
| Proceeds from purchases under the espp | 0 | 143 |
| Proceeds from exercise of stock options | 215 | 20 |
| Net cash provided by financing activities | 215 | 163 |
| Effect of exchange rate changes on cash and cash equivalents | 58 | 299 |
| Net decrease in cash and cash equivalents | -2,787 | -37,600 |
| Cash and cash equivalents at beginning of period | 78,232 | - |
| Cash and cash equivalents at end of period | 37,845 | - |
Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (CNTB)